---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-022732"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2024-06-05T23:59:59+00:00"
generated_at: "2026-06-01T06:10:01.027893+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Elite Pharmaceuticals replaces auditor: Mazars USA succeeded by Forvis Mazars, LLP after Mazars USA merger

## Summary
- Mazars USA resigned as auditor effective June 1, 2024, as substantially all partners/employees joined Forvis, LLP (renamed Forvis Mazars, LLP).
- Forvis Mazars appointed as new independent registered public accounting firm, effective same date, approved by Audit Committee and Board.
- No disagreements or reportable events between company and Mazars USA during past two fiscal years and interim period.
- No prior consultations with Forvis Mazars regarding accounting principles or audit opinions before appointment.

## SEC filing metadata
- accession: 0001493152-24-022732
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2024-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 4.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315224022732/0001493152-24-022732-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315224022732/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-022732
- JSON: https://secwatch.observer/filing/0001493152-24-022732.json
- Plain text: https://secwatch.observer/filing/0001493152-24-022732.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.